Exploiting viral properties for the rational design of modern vaccines

@article{Spohn2008ExploitingVP,
  title={Exploiting viral properties for the rational design of modern vaccines},
  author={Gunther Spohn and Martin F. Bachmann},
  journal={Expert Review of Vaccines},
  year={2008},
  volume={7},
  pages={43 - 54}
}
A major challenge for the future is the development of effective vaccines against chronic infections and the application of therapeutic immunization to the treatment of noninfectious diseases, such as cancer, allergy and autoimmune disorders. In recent years, many of the immunological principles governing the immune response to infectious agents have been clarified and can now be exploited for the rational design of new and better vaccines. As an elucidative example, this review will describe… Expand
Current strategies for subunit and genetic viral veterinary vaccine development.
TLDR
This paper reviews several antigen production and delivery strategies other than those based on the use of live viral vectors, including genetic and protein subunit vaccines as well as alternative production systems. Expand
Virus-like particles: The new frontier of vaccines for animal viral infections
TLDR
The current status of VLPs as a vaccine technology in the veterinary field is reviewed, and the potential advantages and challenges of this technology are discussed. Expand
Design of novel vaccines based on virus-like particles or chimeric virions.
TLDR
This chapter provides an overview on the design and use of VLPs for the development of new generation vaccines. Expand
Adjuvants: no longer a ‘dirty little secret’, but essential key players in vaccines of the future
  • T. Arakawa
  • Biology, Medicine
  • Expert review of vaccines
  • 2011
TLDR
Vaccines that contain killed microbes, such as influenza, polio, Japanese encephalitis, and toxoid-derived vaccines, are safer to use but generally induce weaker immune responses than live-attenuated vaccines. Expand
Virus-like particle-based vaccines for animal viral infections
TLDR
The current status of VLPs as a vaccine strategy in the veterinary field is reviewed and the potential advantages and challenges of this technology are discussed. Expand
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice
TLDR
The superior immunogenicity of the conjugate vaccine with respect to other DIII-based subunit vaccines, its anticipated favourable safety profile and low production costs highlight its potential as an efficacious and cost-effective prophylaxis against WNV. Expand
DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies.
TLDR
It is shown that plasmids encoding Gag of MLV and envelope proteins of VSV or WNV generate retrovirus-derived VLPs pseudotyped with these envelopes expressed in their wild-type conformation, which induce potent humoral responses and highlight the potential of this approach for vaccination strategies aiming at neutralizing antibody induction. Expand
Virus-like particle-based vaccines against hepatitis C virus infection
TLDR
This article summarizes the different VLP-based vaccine approaches that are currently under development and suggests that association of HCV antigens with heterologous structural viral proteins able to form recombinant VLPs is also a promising approach for induction ofHCV-specific immune responses. Expand
Plant-based solutions for veterinary immunotherapeutics and prophylactics
TLDR
The challenges in the process of livestock immunization as well as the current plant biotechnology developments aimed to address these challenges are outlined. Expand
Opportunities and challenges in vaccine delivery.
  • M. G. Carstens
  • Medicine
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2009
TLDR
Key challenges include target identification, mapping the needs and target population, the development and harmonisation of predictive read-out systems and surrogate markers for protection, and improving antigen immunogenicity, delivery and stability. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 102 REFERENCES
Can successful vaccines teach us how to induce efficient protective immune responses?
TLDR
A posteriori deciphering of the biological bases for the efficacy of successful vaccines should be an essential component of research efforts directed at the development of new vaccines for the most challenging infectious diseases. Expand
Therapeutic vaccination to block receptor–ligand interactions
TLDR
Novel therapeutic approaches are focusing on strategies of active immunisation aimed at the induction of a humoral immune response directed against the deleterious receptor–ligand interaction, and have the potential to be developed for clinical use if important safety issues can be properly addressed. Expand
Vaccines: past, present and future
The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccineExpand
Vaccines that facilitate antigen entry into dendritic cells
TLDR
Combined vaccines of the future could use adjuvants such as virus‐like particles and particles targeted towards a predominant cellular type or immune response, with target cell activation enhanced by growth factors or maturation signals prior to, or during immunization. Expand
Therapeutic potential of Toll-like receptor 9 activation
  • A. Krieg
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • 2006
TLDR
An overview of the preclinical data and early human clinical trial results using synthetic oligodeoxynucleotides (ODN) as TLR9 agonists to improve vaccines and treat cancer, infectious disease and allergy/asthma is provided. Expand
ISCOMTM‐based vaccines: The second decade
TLDR
This review focuses on the evaluation of ISCOMTM‐based vaccines in animals over the past 10 years, as well as examining the progress that has been achieved in the development of human vaccines based on ISCOM TM adjuvant technology. Expand
Virus-like particles: flexible platforms for vaccine development
TLDR
This review discusses the development of VLP-based platform technologies for vaccines against pathogens, as well as nontraditional targets such as self-antigens involved in chronic diseases. Expand
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1
TLDR
A new vaccine design, with Ag covalently conjugated to solid core nano-beads of narrowly defined size inducing responses that were significantly higher than those elicited by other bead sizes, and higher than a range of currently used adjuvants. Expand
ISCOMs: an adjuvant with multiple functions
TLDR
This review describes recent developments in theUnderstanding of the structure, composition, and preparation of ISCOMs and will cover important aspects of the understanding of the adjuvant functions of IS COMs and how they act on the immune system. Expand
The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained.
TLDR
The results demonstrate that, with the exception of a notable decline at the highest level of epitope, the magnitude of the responding CTL population generated in vivo following equivalent viral infections is essentially proportional to epitope density. Expand
...
1
2
3
4
5
...